First-in-Class Small Molecule Targeting a Novel Pathway in Parkinson's Disease.

Phenotypically discovered by Ksilink; now transferred to a NewCo.

Product description & Innovation:

KSI-044469: a first-in-class oral, BBB-penetrant small molecule targeting a novel Parkinson's Disease (PD)-linked protease to prevent toxic α-Synuclein (α-Syn) aggregation.

- Discovered through AI-powered phenotypic screening of patient-derived dopaminergic neurons.
- Decreases oligomeric and monomeric α-Synuclein *in vitro* (Figure1).
- Encouraging first *in vivo* experiments in healthy mice (Figure2).
- Strong drug-like properties with clean early safety profile.

Figure 1:



Unmet need & Market:

- > 10 million people affected by PD worldwide[1].
- No disease modifying treatment options available.
- α-Syn accumulation is described as the biological driver of PD[2].
- α-Syn is considered as a hardly druggable target.
- Fast-growing market (≈5% CAGR) reaching US $6 - 8B by 2030[3].

Figure 2:



Positioning – Why invest now:

Our approach is unique to overcome past clinical failures:

- CNS-penetrant small molecule with confirmed brain exposure
- Upstream regulatory activation with preserved neuronal function, driving catalytic intracellular α-syn degradation.
- Non-immunogenic, pathway-driven mechanism without antibody/RNA drawbacks.

Biomarker & Clinical Differentiation:

Our goal is to deliver an oral therapy, enabled by biomarker-based enrichment, for broad synucleinopathy use. The treatment will be fully compatible with symptomatic treatments and potentially preventive as early-detection biomarkers mature.

Key milestones and development plan 2026 - 2030



Fundraising: Seed of 5M€ over 30 months

NewCo planned to raise 5 M€ to nominate PCC & complete IND-enabling studies.



Exit scenarii:

- Licensing at IND (up to 75M€)
- Series A (30-50M€) to reach Phase 1b

CONTACT
Mona Boyé
mona.boye@ksilink.com
Mob: +33 6 88 26 64 04

References: **1)** www.parkinson.org **2)** MJFF's Parkinson's Disease Priority Therapeutic Clinical Pipeline Report Spring 2025 **3)** Grand View Research – Parkinson's Disease Treatment Market Report (2025–2030